Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:80375
Name gastroesophageal adenocarcinoma
Definition A gastroesophageal cancer that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer gastroesophageal cancer gastroesophageal adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ARID1B inact mut unspecified immune checkpoint inhibitor gastroesophageal adenocarcinoma not predictive detail...
ARID2 inact mut unspecified immune checkpoint inhibitor gastroesophageal adenocarcinoma not predictive detail...
PBRM1 inact mut unspecified immune checkpoint inhibitor gastroesophageal adenocarcinoma not predictive detail...
SMARCA4 inact mut unspecified immune checkpoint inhibitor gastroesophageal adenocarcinoma not predictive detail...
SMARCB1 inact mut unspecified immune checkpoint inhibitor gastroesophageal adenocarcinoma not predictive detail...
FGFR2 over exp Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin gastroesophageal adenocarcinoma predicted - sensitive detail...
RAD51C R237* Cisplatin + Fluorouracil + Trastuzumab gastroesophageal adenocarcinoma predicted - sensitive detail...
ATM R1882* Capecitabine + Oxaliplatin gastroesophageal adenocarcinoma predicted - sensitive detail...
ATM W1058* ATM S1993fs Fluorouracil + Leucovorin + Oxaliplatin gastroesophageal adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02578368 Phase III Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT5) Active, not recruiting DEU 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | NLD | FRA | ESP | BEL | AUS 0
NCT02954536 Phase II Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Completed USA 0
NCT03337087 Phase Ib/II Fluorouracil + Leucovorin + Liposomal irinotecan + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Active, not recruiting USA 0
NCT03697304 Phase II Ezabenlimab Miptenalimab Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. Active, not recruiting USA | GBR | CAN 0
NCT03783936 Phase II Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Completed USA 0
NCT03821233 Phase I ZW49 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers Active, not recruiting USA | CAN | AUS 1
NCT03921021 Phase II OBP-301 + Pembrolizumab Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma Completed USA 0
NCT03929666 Phase II Cisplatin + Gemcitabine Cisplatin + Fluorouracil + ZW25 Capecitabine + Oxaliplatin + ZW25 Fluorouracil + Leucovorin + Oxaliplatin + ZW25 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + ZW25 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer Active, not recruiting USA | CAN 2
NCT03986606 Phase I PSB205 A Study of PSB205 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT04021108 Phase II Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Active, not recruiting USA 0
NCT04029922 Phase I MT-5111 Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) Terminated USA | NZL | AUS 0
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA | GBR 0
NCT04150640 Phase II Fluorouracil + Liposomal irinotecan + Oxaliplatin Fluorouracil + Liposomal irinotecan + Oxaliplatin + Trastuzumab P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric Recruiting USA 0
NCT04164979 Phase II Cabozantinib + Pembrolizumab Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma Active, not recruiting USA 0
NCT04166721 Phase Ib/II Atezolizumab + DKN-01 WaKING: Wnt and checKpoint INhibition in Gastric Cancer Active, not recruiting GBR 0
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04511039 Phase I Talazoparib + Trifluridine-tipiracil hydrochloride Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Recruiting USA 0
NCT04522336 Phase I Docetaxel + Fluorouracil + Pembrolizumab Fluorouracil + Oxaliplatin + Pembrolizumab Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer Active, not recruiting USA 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Active, not recruiting USA | ESP 0
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Withdrawn USA 0
NCT04662710 Phase III Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Fluorouracil + Lenvatinib + Leucovorin + Oxaliplatin + Pembrolizumab Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (LEAP-015) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 15
NCT04798781 Phase II Pembrolizumab + Telatinib Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Active, not recruiting USA 0
NCT04879368 Phase III Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Active, not recruiting USA | ITA | ESP | DEU | AUT | AUS 3
NCT04984733 Phase II Nivolumab + Temozolomide Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer (ELEVATE) Recruiting GBR 0
NCT05001347 Phase II Uliledlimab A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors Completed USA 0
NCT05027139 Phase Ib/II Evorpacept + ZW25 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Active, not recruiting USA 0
NCT05041153 Phase I Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Recruiting USA 0
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05143970 Phase I IPH5301 IPH5301 + Paclitaxel + Trastuzumab A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) Recruiting FRA 0
NCT05152147 Phase III Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + ZW25 Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + ZW25 Cisplatin + Fluorouracil + Tislelizumab + ZW25 Capecitabine + Oxaliplatin + Tislelizumab + ZW25 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) Recruiting NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 25
NCT05153304 Phase Ib/II Ipilimumab + Nivolumab A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers Withdrawn USA 0
NCT05427487 Phase I IVX037 Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours Recruiting AUS 0
NCT05523947 Phase Ib/II YH32367 Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor Recruiting AUS 1
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Active, not recruiting ESP | BEL 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ESP | AUS 0
NCT05977322 Phase I 177Lu-FF58 A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Recruiting USA | NLD | ITA | ESP 2
NCT06043427 Phase II Paclitaxel + Ramucirumab Paclitaxel + Ramucirumab + ZW25 Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma Recruiting CAN 0
NCT06123468 Phase Ib/II Sacituzumab govitecan-hziy Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma Recruiting DEU | AUT 0
NCT06154291 Phase Ib/II XON7 FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) Recruiting FRA | BEL 0
NCT06203600 Phase II Paclitaxel + Ramucirumab Nivolumab + Paclitaxel + Ramucirumab Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Recruiting USA 0
NCT06445972 Phase Ib/II Paclitaxel + Ramucirumab Paclitaxel + SKB264 Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Recruiting USA 5
NCT06469944 Phase Ib/II Capecitabine + Oxaliplatin + Pembrolizumab Capecitabine + Pembrolizumab + SKB264 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Pembrolizumab + SKB264 Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Recruiting USA 5
NCT06623396 Phase I ATA2271 A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer Recruiting USA 0